A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia

• Status: Terminated
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety of BMS-852927 after 28 days of dosing in patients with high cholesterol.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Men and women, aged ≥18 to ≤75

• Body mass index (BMI) ≤ 40 kg/m2

• Primary hypercholesterolemia on a stable daily dose of a statin for ≥ 6 weeks

• Serum triglyceride levels at screening < 400mg/dL (< 4.52 mmol/L)

Exclusion Criteria:

• Any significant acute medical illness, significant cardiovascular history

• Current or history of hepatic or hepatobiliary disease

• Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population